Loading...

CYCC CYCLACEL PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

CYCL

CYCC

CYCLACEL PHARMACEUTICALS INC

(CYCC)

2025 8-K

Show Summary

Show Summary

Increase in Dividend Rate

Financial Statements

Merger of Equals

Dividend Declaration

Management Changes

Securities Agreement

Leadership Changes

Share Purchase Agreement

Stock Amendments

Capital Structure Changes

Subsidiary Liquidation

Agreement Amendment

Stock Sale Agreement

Q3 Financial Results

Nasdaq Delisting Risk

Dividend Suspension

Nasdaq Delisting Risk

Nasdaq Compliance Issue

Accounting Firm Change

Financial Results

Annual Meeting and Manageme...

Earnings Reports

Private Placement

Earnings Reports

Management Changes

Dividend Declaration

Investor Conferences

Compliance with Nasdaq mini...

Securities Purchase Agreement

Special Meeting

Restatement of Financial St...

Earnings Reports

Bylaw Amendment

Dividend Declaration

Earnings Reports

Annual Meeting and Dividend...

Earnings Reports

Renewal of Employment Agree...

Regulation FD Disclosure

Dividend Declaration

Earnings Reports

External Links:

Cyclacel Pharmaceuticals entered into a Securities Purchase Agreement with David E. Lazar to sell 1,000,000 shares of Series C and 2,100,000 shares of Series D Convertible Preferred Stock for $3.1 million, which will be used to settle liabilities and

AI Assistant

CYCLACEL PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.